BUZZ-NovaBridge 股价上涨,因眼病药物中期试验显现前景

路透中文
Mar 09
BUZZ-NovaBridge 股价上涨,因眼病药物中期试验显现前景

3月9日 - ** 药物开发商NovaBridgeNBP.O股价盘前上涨6.6%至3.73美元

** 该公司称其试验性药物VIS-101改善了湿性老年黄斑变性患者的视力,这种疾病会损害视网膜并导致老年人视力下降

** 在一项中期研究中,患者在标准视力表上的视力提高了 10 个字母以上,视网膜肿胀也有所减轻

** 称试验中的 38 名患者中有近一半在服用 3 次药物后 6 个月内无需再接受治疗

** VIS-101耐受性良好,没有出现严重的安全性问题--公司称

** NBP计划在2026年下半年开展更大规模的剂量测定研究,并在2027年开展全球后期试验

** 2025 年股价上涨近四倍

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10